国药现代：产品“盐酸戊乙奎醚注射液”取得注册证

Core Viewpoint - The company Guoyao Modern has received approval from the National Medical Products Administration for its product, "Pentazocine Hydrochloride Injection," which may enhance its market position and revenue potential in the pharmaceutical sector [1]. Company Summary - Guoyao Modern's subsidiary, Shanghai Modern Pharmaceutical Co., Ltd., has obtained a drug registration certificate for Pentazocine Hydrochloride Injection [1]. - As of the latest report, Guoyao Modern's market capitalization stands at 14.8 billion yuan [1]. Revenue Composition - For the year 2024, Guoyao Modern's revenue composition is as follows: - Formulations account for 49.84% - Intermediates and raw materials account for 47.53% - Other businesses account for 2.44% - Health-related products account for 0.19% [1].